Aurora Cannabis (ACB) is expanding its Aurora medical portfolio in Australia and New Zealand, delivering patients and prescribers enhanced choice, reliable quality, and easier access to science-backed products. The expansion underscores the company’s ongoing dedication to meeting the unique needs of patients and healthcare professionals in the region, reflecting Aurora’s strategic focus on long-term global growth. The expansion in New Zealand this month includes two new THC flower products – Big Wave, Night Ride, as well as the balanced strain, Half Moon coming soon in Q1 FY27. The brand will also debut four new resin cartridges in Australia this month including, Chemango Kush, Cosmic Cream, Lunar Express, and Soul Train Haze.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACB:
- Aurora Cannabis price target lowered to C$9 from C$10 at Canaccord
- Aurora Cannabis: Divestiture-Driven Margin Uplift and Improved Growth Outlook Support Buy Rating
- Aurora Cannabis Earnings Call Highlights Medical-First Pivot
- Aurora Cannabis Sets Up US$100 Million ATM Equity Program With TD Securities
- Aurora Cannabis Launches US$100 Million At-the-Market Equity Program to Fund Growth